Additional data from CheckMate 274 showed that adjuvant nivolumab benefits patients with muscle-invasive bladder cancer with ...
Nivolumab plus ipilimumab is being reviewed by the FDA as a first-line treatment for advanced colorectal cancer, with a ...
HealthDay on MSN6d
Nivolumab Added to Chemo Improves Response in ER+, HER2− Breast Cancer(HealthDay News) — For patients with high-risk, early-stage estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative primary breast cancer (BC), adding nivolumab to ...
Bristol Myers' Opdivo plus Yervoy gets FDA Priority Review for first-line MSI-H/dMMR metastatic colorectal cancer, with a ...
Kathryn Beckermann, MD, PhD, discusses the patient-reported outcomes for tivozanib plus nivolumab from the phase 3 TiNivo-2 ...
The application was based on results from the three-arm Phase 3 CheckMate -8HW study.
The FDA has started a priority review of Bristol Myers Squibb's Opdivo and Yervoy as a first-line therapy for patients with a ...
Bristol Myers Squibb & Co (NYSE:BMY) announced the final analysis of overall survival (OS) from the Phase 3 CheckMate -816 ...
A combination immunotherapy may help cure a majority of patients with melanoma -- a deadly skin cancer -- that has spread to ...
Pancreatic cancer reprograms nerve cells to fuel its growth, but blocking these connections can shrink tumors and boost ...
A new study shows that neutralising GDF-15 restores immune response in advanced cancers resistant to PD-1 blockade.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback